← Back to Search

Non-invasive Brain Stimulation

TMS for Schizophrenia

N/A

Recruiting

Led By L E Hong, MD

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male and Female between ages 21-62

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

Study Summary

This trial is testing whether electrical stimulations to the prefrontal cortex can help reduce symptoms in people with schizophrenia, specifically auditory hallucinations and poor working memory/sustained attention.

Who is the study for?

This trial is for adults aged 21-62 with schizophrenia, stable on their current medication for at least 4 weeks. They must be able to consent and not have a history of seizures, family epilepsy, significant substance abuse recently (except nicotine or marijuana), or take high doses of clozapine. Pregnant women and those with metal implants near the head can't participate.Check my eligibility

What is being tested?

The study tests if targeted repetitive TMS (a non-invasive brain stimulation) to the prefrontal cortex can improve symptoms like auditory hallucinations and attention in schizophrenia patients. It compares active rTMS against sham (fake) treatment to see if it corrects abnormal brain activity.See study design

What are the potential side effects?

rTMS may cause discomfort at the stimulation site, headache, lightheadedness, or twitching facial muscles during treatment. Seizures are rare but possible; hence people with seizure history aren't eligible.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21 and 62 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Clinician's Questionnaire for Auditory Hallucinations (CQAH) is used to evaluate the treatment effect of rTMS on auditory hallucination in schizophrenia.

Secondary outcome measures

Electroencephalogram (EEG) is used to evaluate the brain electrical activities that are corresponding to the treatment effect on auditory hallucination.

Brain

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Active rTMS stimulationActive Control1 Intervention

Real active rTMS stimulation.

Group II: Sham rTMS stimulationPlacebo Group1 Intervention

Sham repetitive TMS stimulation.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor

688 Previous Clinical Trials

374,526 Total Patients Enrolled

66 Trials studying Schizophrenia

10,127 Patients Enrolled for Schizophrenia

L E Hong, MDPrincipal InvestigatorUniversity of Maryland, Baltimore

Media Library

Active rTMS stimulation (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT02916810 — N/A

Schizophrenia Research Study Groups: Active rTMS stimulation, Sham rTMS stimulation

Schizophrenia Clinical Trial 2023: Active rTMS stimulation Highlights & Side Effects. Trial Name: NCT02916810 — N/A

Active rTMS stimulation (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02916810 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are octogenarians being accepted into the experimental cohort?

"This trial is enrolling participants ranging from 21 to 62 years of age."

Answered by AI

What are the eligibility requirements for involvement in this experiment?

"This clinical trial is seeking 130 subjects aged between 21 and 62 who have been diagnosed with behavioral disorders. To be eligible, participants must also conform to the following requirements: of either gender, able to provide written consent (at least 21 years old), a score of 10 or greater on Evaluation to Sign Consent (ESC) tests, and demonstrate 4 weeks of medication stability at same dosages."

Answered by AI

How many participants are being monitored in this experiment?

"Yes, the information posted to clinicaltrials.gov indicates that this study is actively enrolling patients. The trial was first made public on October 1st 2016 and has been edited as recent as October 10th 2022. A total of 130 people must be recruited from a single medical centre for the experiment to take place."

Answered by AI

Are there any openings for enrolment in this experiment?

"That is correct. According to the clinicaltrials.gov website, this medical study first appeared on October 1st 2016 and was recently updated on October 10th 2022; it currently requires 130 participants from a single site for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

TMS for Symptom Reduction in Schizophrenia

L. Elliot Hong 2016. "TMS for Symptom Reduction in Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02916810.

All > Transcranial Magnetic Stimulation